FDA panel votes 3-14 that Abbott (ABT) has not found right Humira dose
- Stocks dip as earnings pour in, consumer discretionary lags
- UPDATE: Alphabet (GOOG) Tops Q3 EPS Views; Revs Strong
- Twitter (TWTR) Tops Q3 EPS by 4c; Announces Restructuring, Workforce Reduction
- Cirrus Logic, Inc. (CRUS) Q2 Results and Guidance Beat Estimates
- Amazon.com (AMZN) Misses Q3 EPS by 26c, Offers Q4 Guidance
FDA panel votes 3-14 that Abbott (NYSE: ABT) has not found right Humira dose.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Abbott (ABT) Announces Publication of Positive Infant Formula with 2'-FL Human Milk Oligosaccharide+ Data
- TG Therapeutics (TGTX) Announces Publication of TGR-1202 Preclinical Data
- Latest Fox News Poll Shows Tighter Race Between Clinton and Trump
Create E-mail Alert Related CategoriesFDA, General News
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!